New hope for kids with kidney disease: dupilumab trial aims to stop relapses
NCT ID NCT07091175
First seen Jan 09, 2026 · Last updated May 16, 2026 · Updated 14 times
Summary
This study tests if dupilumab can help children with severe nephrotic syndrome stay relapse-free longer. About 66 kids aged 6-18 will receive either dupilumab or a placebo injection every 2-4 weeks for 6 months, while slowly reducing their steroid dose. The goal is to see if dupilumab reduces the time to relapse and to check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEPHROTIC SYNDROME IN CHILDREN are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
KK Women's and Children's Hospital
RECRUITINGSingapore, Singapore, 229899, Singapore
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
National University Hospital
RECRUITINGSingapore, Singapore, 119228, Singapore
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.